Computational Biology, Target Sciences, Research and Development (R&D), GlaxoSmithKline, Collegeville, Pennsylvania, USA.
National Heart and Lung Institute, Imperial College London, London, UK.
Thorax. 2018 Apr;73(4):331-338. doi: 10.1136/thoraxjnl-2017-210741. Epub 2017 Dec 21.
Recent studies suggest that lung microbiome dysbiosis, the disease associated disruption of the lung microbial community, might play a key role in chronic obstructive pulmonary disease (COPD) exacerbations. However, characterising temporal variability of the microbiome from large longitudinal COPD cohorts is needed to better understand this phenomenon.
We performed a 16S ribosomal RNA survey of microbiome on 716 sputum samples collected longitudinally at baseline and exacerbations from 281 subjects with COPD at three UK clinical centres as part of the COPDMAP consortium.
The microbiome composition was similar among centres and between stable and exacerbations except for a small significant decrease of at exacerbations. The abundance of was negatively associated with bacterial alpha diversity. Microbiomes were distinct between exacerbations associated with bacteria versus eosinophilic airway inflammation. Dysbiosis at exacerbations, measured as significant within subject deviation of microbial composition relative to baseline, was present in 41% of exacerbations. Dysbiosis was associated with increased exacerbation severity indicated by a greater fall in forced expiratory volume in one second, forced vital capacity and a greater increase in CAT score, particularly in exacerbations with concurrent eosinophilic inflammation. There was a significant difference of temporal variability of microbial alpha and beta diversity among centres. The variation of beta diversity significantly decreased in those subjects with frequent historical exacerbations.
Microbial dysbiosis is a feature of some exacerbations and its presence, especially in concert with eosinophilic inflammation, is associated with more severe exacerbations indicated by a greater fall in lung function.
Results, NCT01620645.
最近的研究表明,肺部微生物组失调,即与肺部微生物群落紊乱相关的疾病,可能在慢性阻塞性肺疾病(COPD)加重中发挥关键作用。然而,需要对大型 COPD 纵向队列的微生物组进行时间变异性特征描述,以更好地理解这一现象。
我们对 COPDMAP 联盟的 281 名 COPD 患者的 716 份痰液样本进行了 16S 核糖体 RNA 微生物组调查,这些样本是在三个英国临床中心的基线和加重期纵向采集的。
微生物组组成在中心之间以及稳定期和加重期之间相似,除了在加重期时略有显著下降。的丰度与细菌α多样性呈负相关。与细菌相关的加重期与嗜酸性气道炎症相关的加重期的微生物组明显不同。在 41%的加重期中存在相对基线而言微生物组成的显著个体内偏差,定义为加重期的失调。失调与加重期严重程度相关,表现为用力呼气量一秒率、用力肺活量的更大下降以及 CAT 评分的更大增加,尤其是在合并嗜酸性炎症的加重期中。中心之间微生物α和β多样性的时间变异性存在显著差异。在有频繁既往加重史的患者中,β多样性的变异性显著降低。
微生物失调是一些加重期的特征,其存在,尤其是与嗜酸性炎症同时存在,与肺功能下降更大的加重期相关,表明加重期更严重。
结果,NCT01620645。